AstraZeneca Settles Pulmicort War With Teva

Law360, New York (November 25, 2008, 12:00 AM EST) -- Coaxed by favorable royalty rates and an affirmation of its patents, AstraZeneca PLC has agreed to let Teva Pharmaceuticals Ltd. market a generic version of Pulmicort Respules, AstraZeneca’s asthma medication, bringing three years of hard-fought litigation to a close.

While the terms of the agreement remain confidential, AstraZeneca announced Tuesday that it had entered a settlement in its patent litigation with Teva’s subsidiary Ivax Pharmaceuticals Inc., granting Teva exclusive license to the treatment and scratching the trial scheduled for January.

Under the settlement, Teva acknowledges the...
To view the full article, register now.